Literature DB >> 11263710

Development of a shorter version of the geriatric depression scale for visually impaired older patients.

I I Galaria1, R J Casten, B W Rovner.   

Abstract

OBJECTIVE: To validate a shorter version of the Geriatric Depression Scale (GDS) for older, visually impaired patients. PARTICIPANTS: Subjects were 70 visually impaired adults over age 65 who were presenting for services at a low vision clinic.
METHOD: Subjects were interviewed by a geriatric nurse practitioner. A structured clinical interview was used to ascertain major depression, and the 15-item GDS was used to assess depressive symptoms. A multiple logistic regression was performed in which the dependent variable was clinical diagnosis of major depression and the independent variables were the 15 GDS items. Four items were significant, and were used to form the GDS-Abbreviated (GDS-A) scale. Sensitivity and specificity analyses were performed on various combinations of these four items to generate an effective cutoff score.
RESULTS: Endorsing any two or more of the following four items--a) dissatisfied with life, (b) feeling helpless, (c) reporting problems with memory, and (d) lost activities and interests-yielded the best results with a sensitivity of .71 and a specificity of .88. This GDS-A cutoff score better differentiates depressed from nondepressed individuals than the cutoff score of 5 that is recommended for the GDS-15.
CONCLUSION: The GDS-A's short format and strong discriminating ability make it an effective, convenient tool for screening visually impaired, older patients for depression.

Entities:  

Mesh:

Year:  2000        PMID: 11263710     DOI: 10.1017/s1041610200006554

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  6 in total

Review 1.  What is the cost of blindness?

Authors:  C Meads; C Hyde
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

2.  The Prevalence of Depression and Depressive Symptoms among Eye Disease Patients: A Systematic Review and Meta-analysis.

Authors:  Yajing Zheng; Xiaohang Wu; Xiaoming Lin; Haotian Lin
Journal:  Sci Rep       Date:  2017-04-12       Impact factor: 4.379

Review 3.  Case identification of depression in patients with chronic physical health problems: a diagnostic accuracy meta-analysis of 113 studies.

Authors:  Nicholas Meader; Alex J Mitchell; Carolyn Chew-Graham; David Goldberg; Maria Rizzo; Victoria Bird; David Kessler; Jon Packham; Mark Haddad; Stephen Pilling
Journal:  Br J Gen Pract       Date:  2011-12       Impact factor: 5.386

4.  Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Authors:  Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

5.  Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.

Authors:  Sorrel E Wolowacz; Neil Roskell; Steven Kelly; Fiona M Maciver; Chris S Brand
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

6.  Prevalence and pattern of cognitive impairment in rural and urban populations from Northern Portugal.

Authors:  Belina Nunes; Ricardo D Silva; Vitor T Cruz; Jose M Roriz; Joana Pais; Maria C Silva
Journal:  BMC Neurol       Date:  2010-06-11       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.